Ibrutinib combination regimen shows substantial benefits in relapsed CLL

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Extensive lymph node surgery may not be necessary for some patients with melanoma

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Extensive lymph node surgery may not be necessary for some patients with melanoma

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis